BioCryst Pharmaceuticals | BCRX - Przychody Ze Sprzedaży





Obroty Zmiana Data
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
BioCryst Pharmaceuticals USD 218.25M 188.3M 2026-06
Chugai Pharma JPY 341.6B 19.85B 2026-06
Daiichi Sankyo JPY 574.74B 12.26B 2026-06
DBV Technologies USD 645K 2.13M 2025-12
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Gilead Sciences USD 7.8B 800M 2026-06
GlaxoSmithKline GBP 8.41B 781M 2026-06
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Karyopharm Therapeutics USD 35.07M 987K 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Novavax USD 147.14M 76.69M 2025-12
PTC Therapeutics USD 361M 88M 2026-06
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Roche Holding CHF 30.36B 14.71B 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06